This book provides a comprehensive overview of synthetic polymers and their applications in designing delivery systems for the management of inflammatory diseases. It presents introductory insights into inflammatory conditions, delves into the role of synthetic polymers, and examines diverse delivery approaches. Synthetic Polymeric Materials-Based Drug Delivery Systems for Inflammatory Diseases explores the potential of synthetic polymers in designing drug delivery systems for managing inflammatory diseases, including inflammatory lung diseases, inflammatory bowel diseases, and inflammatory skin diseases, as well as other conditions like cancer, neurodegenerative disorders, rheumatoid arthritis, and eye-related inflammatory conditions. It also discusses the role of synthetic polymers in modulating immune system responses in different disease conditions. Furthermore, it analyzes the 3D printing technologies employed for the preparation of drug delivery systems based on synthetic polymers. Toward the end, the book highlights the challenges and prospects of synthetic polymers in designing delivery systems for the effective management of inflammatory diseases and their clinical usage. This book is intended for researchers and professionals in the fields of pharmaceutical sciences, nanotechnology, and drug delivery systems.

Key Features

• Highlights the role of a synthetic polymer-based drug delivery system against inflammatory responses
• Explores the cutting-edge technology of 3D printing and its application in preparing drug delivery systems based on synthetic polymers
• Provides valuable insights into how synthetic polymers can be used to modulate immune system responses
• Presents regulatory compliance using synthetic polymers in drug delivery systems for inflammatory diseases

• Examines challenges associated with synthetic polymers in drug delivery systems for inflammatory diseases

  Autorentext

  Dr. Harish Dureja, is presently the Dean, Research & Development and Dean, Faculty of Pharmaceutical Sciences at Maharshi Dayanand University, Rohtak, and a Visiting Professor at ARCCIM, Faculty of Health, University of Technology Sydney, Australia, and Adjunct Professor, School of Medical and Life Sciences, Sunway University, Kuala Lumpur, Malaysia. He has dedicated the past 25 years to teaching, research, mentoring, advising, and administration. He is actively engaged in the fields of drug delivery and regulatory science, focusing on enhancing the oral bioavailability of BCS class II drugs, developing nanoparticulate drug delivery systems, conducting in silico ADME modeling, and managing pharmaceutical regulatory affairs. Dr. Dureja holds one Indian patent and has authored over 300 research articles in various respected international and national journals. Additionally, he has authored six books and contributed to thirty-six book chapters published by both national and international publishers.

Dr. Vimal Arora currently holds the position of Professor and Associate Director at University Institute of Pharma Sciences, Chandigarh University, Punjab, India. With a career spanning nineteen years, he has dedicated his expertise to the fields of pharmaceutical education and research, focusing on pharmaceutical product development and quality assurance. Dr. Arora's academic contributions include over 60 research articles, a book, 15 book chapters, two Indian design registrations and three Indian patents. His work is prominently centered on the exploration of innovative techniques for designing drug delivery systems aimed at treating cancer and diabetes.

Professor Paul A. McCarron currently holds a Chair in Pharmaceutics and serves as the Head of the School of Pharmacy and Pharmaceutical Sciences at Ulster University. As a registered pharmacist and a member of the Pharmaceutical Society of Northern Ireland, he possesses a wealth of experience in both industrial and academic pharmacy. Professor McCarron has a specific passion for advancing drug delivery systems and excels in translating innovative delivery strategies into clinical and commercial applications. Currently, he holds the role of company director at Swedish Pharma and is the founder of Jenarron Therapeutics Ltd. Professor McCarron's research interests revolve around the development and characterization of nanoparticulate systems and topical formulations. Supported by substantial funding from the Research and Development Office in Northern Ireland, he successfully developed and trialed an innovative putty-type material for administering anesthesia to acute lacerations.

Dr. Vandana B. Patravale presently serves as a Professor of Pharmaceutics at the Institute of Chemical Technology in Mumbai, India. With over 30 years of experience in teaching and research, she has made significant contributions to her field. Dr. Patravale has published four books and 35 book chapters with international publishers. Her research primarily focuses on the development of nanocarriers, with a strong emphasis on addressing infectious diseases, cancer, and neurodegenerative disorders, many of which are linked to inflammation. Notably, she has successfully transferred more than 20 technologies to the industry.

Dr. Kamal Dua, Associate Professor, Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney (UTS), has over 12 years of research experience working in the field of drug delivery targeting inflammatory diseases. Dr. Dua is also a Node Leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr. Dua researches in two complementary areas: drug delivery and immunology, specifically addressing how these disciplines can advance one another, helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua's research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as interleukins and microRNAs and developing new and effective drug delivery formulations for the management of inflammation in chronic airway diseases and cancer.